Restoring neurotransmitter balance for the treatment of stress and anxiety

Anxiety and stress disorders often stem from imbalances in the brain’s neurotransmitter systems, which can disrupt emotional regulation and cognitive function. Utilizing our deep expertise in ion channel biology, medicinal chemistry, formulation development and translational sciences, we design best-in-class oral, small molecules to modulate neurotransmission and downstream signaling in the brain.

OUR PIPELINE

The growing challenge of anxiety and PTSD

Nearly one-third of people in the U.S. will face an anxiety disorder in their lifetime, and about 7% will experience PTSD. Despite these staggering numbers, current treatments come with significant drawbacks, including sedation, cognitive impairment, and addiction risks. The need for better solutions has never been clearer.

READ THE STUDY

A breakthrough in treatment potential

BNC210, our proprietary small molecule in Phase 3 clinical development, is poised to transform the standard of care for Social Anxiety Disorder (SAD) and Post-Traumatic Stress Disorder (PTSD). Unlike current options, BNC210’s emerging profile may offer:

Fast-acting as-needed and chronic relief

Holds the promise of delivering rapid anxiety relief tailored to individual needs. Whether taken “as needed” for immediate support or used daily for ongoing symptom management, it adapts to your lifestyle without compromising effectiveness.

No sedation, addiction risks, or cognitive side effects

BNC210’s emerging profile suggests that unlike traditional treatments, BNC210 works without causing drowsiness, dependency, or mental fog. It’s designed to empower patients with clarity and control, ensuring relief without unwanted trade-offs.

A novel mechanism of action

BNC210 targets neurotransmitter balance in a safe and effective way. Its unique mechanism, offering a fresh path to anxiety relief.

A unique mechanism for better outcomes

BNC210 works as a negative allosteric modulator of the α7 nicotinic acetylcholine receptor (α7 nAChR). This differentiated mechanism has shown promise in multiple studies for treating SAD, PTSD, and related neuropsychiatric disorders—offering hope for rapid and long-lasting, broad-spectrum anxiety and stress relief.

READ THE STUDY

Clinical results that inspire confidence

In clinical trials, BNC210 has demonstrated rapid anti-anxiety and anti-depressive effects without the common drawbacks of existing treatments, such as sedation, memory impairment, or addiction risks. Our data highlight its potential to outperform the current standard of care with benzodiazepines, SSRIs, and SNRIs.

READ THE STUDY

The Next Chapter in Mental Healthcare

BNC210 is currently advancing through late-stage trials for SAD and PTSD, with potential applications in generalized anxiety disorder (GAD), panic attacks, and beyond.

Our Next-Generation α7 NAM Program builds on this foundation with patented molecules targeting CNS disorders, driven by our expertise in ion channel biology and translational medicine. Together, we’re shaping a future of innovative treatments for people suffering from mental health disorders.

OUR PIPELINE

Contact us today

Discover how our groundbreaking technology is transforming mental health—contact us today to learn more.